WebJun 15, 2024 · Paul, Weiss advised General Atlantic in its investment in Royalty Pharma PLC, a leading funder of innovation across the biopharmaceutical industry, and Royalty … WebSenior Leadership Team. Pablo Legorreta. Founder & Chief Executive Officer. Sandy Balkin, PhD. Strategy & Analytics. Terrance Coyne. Chief Financial Officer. George Grofik, CFA. Head of Investor Relations & Communications.
Royalty Pharma soars in market debut - The Globe and Mail
WebAs of 7th November 2024, General Atlantic, L.P.’s top holding is 97,209,436 shares of EngageSmart currently worth over $2.01 billion and making up 23.7% of the portfolio value. Relative to the number of outstanding shares of EngageSmart, General Atlantic, L.P. owns more than 0.6% of the company. In addition, the fund holds 61,384,475 shares ... WebMay 24, 2024 · Prior to joining General Atlantic, Robb was an analyst at Greenhill & Co. He graduated with a B.S. in Finance from the McIntire School of Commerce at the University of Virginia. “For over 40 years, General Atlantic has been a global growth equity investor that partners with visionary business leaders during the most challenging phases of ... resch tickets
Leadership Team - Royalty Pharma
WebNov 18, 2024 · General Atlantic is a leading global growth equity firm providing capital and strategic support for growth companies. Established in 1980, General Atlantic combines … WebDec 8, 2024 · He was also involved in the firm’s investments in Adagene, CANbridge, Chi-Med, Immunocore, Ocumension, PathAI, Pharvaris and Royalty Pharma. Prior to joining … WebJun 15, 2024 · Royalty Pharma is a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals, and … pros and cons about dogs